

PRESS RELEASE  
16 June 2022 11:55:00 CEST



## ProstaLund signs distribution agreement for Israel

**ProstaLund AB has signed an exclusive distribution agreement with the Israeli company AMI Technologies Ltd. The agreement is expected to generate revenues of just over SEK 1 million during the first 18 months of the agreement period.**

Earlier this year, ProstaLund began its internationalization outside the Nordic region with a distribution agreement for the UK. The next step in this process is now being taken when a distribution agreement has been signed for Israel with AMI Technologies Ltd.

AMI Technologies Ltd is a leading Israeli medical technology marketing company. The company was founded in 1986 and is committed to implementing advanced, innovative technologies in Israel. They represent state-of-the-art international medical device companies, from USA and Europe, which are at the forefront of design and development of advanced products that create value for the benefit of both the profession and patients. In urology, AMI has a broad portfolio of products from many reputable companies.

The distribution agreement has been preceded by a visit to Sweden from AMI together with Israeli urology professor in April where they attended CoreTherm® treatments and saw the use of the Schelin Catheter™ and CoreFlow® - Soft Stent.

Initially, AMI will focus on CoreFlow® and the Schelin Catheter, but there is also an interest in CoreTherm®, especially when the new platform is CE marked. As ProstaLund's products are CE marked, no further time- and cost-intensive registration process is required in Israel.

Tali Schachter, CEO, AMI Technologies Ltd, comments: "Our experience is that ProstaLund works very professionally with innovative products that will add great value to the Israeli urological profession going forward. "

"Our entry into the UK had ripple effects. Our new agreement with AMI is a clear proof of this and shows that both the company and our product portfolio are very interesting for both the urological profession and distributors outside the Nordic borders.", says CEO Johan Wennerholm in a comment.

**For further information, please contact:**

---

Johan Wennerholm, CEO  
Tel. +46 (0) 730 429997  
Email: [johan.wennerholm@prostalund.com](mailto:johan.wennerholm@prostalund.com)



PRESS RELEASE  
16 June 2022 11:55:00 CEST

## About ProstaLund

---

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

### **Certified Adviser:**

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

*This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-06-16 11:55 CEST.*

## Attachments

---

ProstaLund signs distribution agreement for Israel